Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-MAL-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
LENTI-MAL-01 is a preclinical-stage, non-replicative, non-integrative lentiviral vector-based vaccine candidate being developed by Theravectys for the prophylactic prevention of malaria. The vaccine utilizes Theravectys's proprietary lentiviral vector platform, which is designed to target dendritic cells in vivo and elicit a robust, long-lasting cellular (T-cell) and humoral immune response without the need for an adjuvant. Preclinical studies of the platform have demonstrated sterile cellular immunity against liver-stage malaria.
02
Targets
CD36 (CD36 antigen)CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on LENTI-MAL-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-MAL-01.